ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Contract Amendment
On May 5, 2017, the Company entered into an amendment to the
Amended and Restated Consulting Agreement, dated August 6, 2015
(the Consulting Agreement) with Mr. Sandesh Seth, our Executive
Chairman (the Amendment). to the Amendment the term of the
Consulting Agreement was extended from August 11, 2019 to
February 21, 2021. All other provisions of the Consulting
Agreement remain unchanged. The Amendment is attached hereto as
Exhibit 10.1 and is incorporated herein by reference. The above
description of the Amendment is only a summary of the terms of
the Amendment, and does not purport to be a complete description
of such document, and is qualified in its entirety by reference
to the Amendment, a copy of which is attached as an exhibit
hereto and which is incorporated by reference into this Item 1.01
and Item 5.02.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 10.1 |
Amendment to Amended and Restated Consulting Agreement, dated May 5, 2017, between Sandesh Seth and Actinium Pharmaceuticals, Inc. |
About ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM)
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials. ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Recent Trading Information
ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) closed its last trading session 00.00 at 1.42 with 388,015 shares trading hands.